Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have been given an average recommendation of “Buy” by the seven analysts that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $8.67.
MNKD has been the topic of several research analyst reports. Leerink Partners started coverage on shares of MannKind in a research report on Monday, September 9th. They set an “outperform” rating and a $8.00 price target on the stock. Oppenheimer increased their target price on MannKind from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. Finally, Leerink Partnrs upgraded MannKind to a “strong-buy” rating in a report on Monday, September 9th.
View Our Latest Report on MannKind
Insiders Place Their Bets
Institutional Trading of MannKind
A number of large investors have recently modified their holdings of the company. Millennium Management LLC boosted its stake in MannKind by 189.8% during the 2nd quarter. Millennium Management LLC now owns 4,744,519 shares of the biopharmaceutical company’s stock valued at $24,766,000 after purchasing an additional 3,107,598 shares during the period. TSP Capital Management Group LLC boosted its position in shares of MannKind by 196.0% during the second quarter. TSP Capital Management Group LLC now owns 2,391,900 shares of the biopharmaceutical company’s stock worth $12,486,000 after buying an additional 1,583,800 shares during the period. Dimensional Fund Advisors LP bought a new position in MannKind in the 2nd quarter worth approximately $1,524,000. Dark Forest Capital Management LP increased its position in MannKind by 1,551.2% in the 2nd quarter. Dark Forest Capital Management LP now owns 275,970 shares of the biopharmaceutical company’s stock valued at $1,441,000 after acquiring an additional 259,257 shares during the period. Finally, 180 Wealth Advisors LLC raised its stake in MannKind by 12.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 1,942,210 shares of the biopharmaceutical company’s stock valued at $8,798,000 after acquiring an additional 216,880 shares in the last quarter. Institutional investors and hedge funds own 49.55% of the company’s stock.
MannKind Price Performance
MNKD stock opened at $6.60 on Thursday. MannKind has a 52-week low of $3.17 and a 52-week high of $6.92. The company has a market capitalization of $1.80 billion, a PE ratio of 220.00 and a beta of 1.31. The stock’s 50 day moving average is $6.09 and its two-hundred day moving average is $5.28.
MannKind (NASDAQ:MNKD – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The firm had revenue of $72.39 million for the quarter, compared to the consensus estimate of $64.81 million. MannKind had a net margin of 4.73% and a negative return on equity of 11.97%. The firm’s revenue was up 48.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.02) EPS. As a group, sell-side analysts anticipate that MannKind will post 0.11 EPS for the current year.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Featured Articles
- Five stocks we like better than MannKind
- What Investors Need to Know About Upcoming IPOs
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Plot Fibonacci Price Inflection Levels
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.